Euroopan unioni - italia - EMA (European Medicines Agency)

hra pharma rare diseases - ketoconazole - sindrome di cushing - antimicotici per uso sistemico - ketoconazole hra è indicato per il trattamento della sindrome di cushing endogena in adulti e adolescenti di età superiore ai 12 anni.

Yhdysvallat - englanti - NLM (National Library of Medicine)

a-s medication solutions - ketoconazole (unii: r9400w927i) (ketoconazole - unii:r9400w927i) - ketoconazole cream 2% is indicated for the topical treatment of tinea corporis, tinea cruris and tinea pedis caused by trichophyton rubrum, t. mentagrophytes and epidermophyton floccosum; in the treatment of tinea (pityriasis) versicolor caused by malassezia furfur (pityrosporum orbiculare) ; in the treatment of cutaneous candidiasis caused by candida spp. and in the treatment of seborrheic dermatitis. ketoconazole cream 2% is contraindicated in persons who have shown hypersensitivity to the active or excipient ingredients of this formulation.

Yhdysvallat - englanti - NLM (National Library of Medicine)

a-s medication solutions - ketoconazole (unii: r9400w927i) (ketoconazole - unii:r9400w927i) - ketoconazole cream, 2% is indicated for the topical treatment of tinea corporis, tinea cruris and tinea pedis caused by trichophyton rubrum , t. mentagrophytes and epidermophyton floccosum ; in the treatment of tinea (pityriasis) versicolor caused by malassezia furfur (pityrosporum orbiculare) ; and in the treatment of cutaneous candidiasis caused by candida spp . ketoconazole cream, 2% is contraindicated in persons who have shown hypersensitivity to the active or excipient ingredients of this formulation.

Yhdysvallat - englanti - NLM (National Library of Medicine)

a-s medication solutions - ketoconazole (unii: r9400w927i) (ketoconazole - unii:r9400w927i) - ketoconazole cream, 2% is indicated for the topical treatment of tinea corporis, tinea cruris and tinea pedis caused by trichophyton rubrum , t. mentagrophytes and epidermophyton floccosum ; in the treatment of tinea (pityriasis) versicolor caused by malassezia furfur (pityrosporum orbiculare) ; and in the treatment of cutaneous candidiasis caused by candida spp . ketoconazole cream, 2% is contraindicated in persons who have shown hypersensitivity to the active or excipient ingredients of this formulation.

Yhdysvallat - englanti - NLM (National Library of Medicine)

a-s medication solutions - ketoconazole (unii: r9400w927i) (ketoconazole - unii:r9400w927i) - ketoconazole cream, 2% is indicated for the topical treatment of tinea corporis, tinea cruris and tinea pedis caused by trichophyton rubrum , t. mentagrophytes and epidermophyton floccosum ; in the treatment of tinea (pityriasis) versicolor caused by malassezia furfur (pityrosporum orbiculare) ; and in the treatment of cutaneous candidiasis caused by candida spp . and in the treatment of seborrheic dermatitis. ketoconazole cream, 2% is contraindicated in persons who have shown hypersensitivity to the active or excipient ingredients of this formulation.

Euroopan unioni - ranska - EMA (European Medicines Agency)

hra pharma rare diseases - le kétoconazole - syndrome de cushing - antimycotiques pour une utilisation systémique - ketoconazole hra est indiqué pour le traitement du syndrome de cushing endogène chez les adultes et les adolescents de plus de 12 ans.

Yhdysvallat - englanti - NLM (National Library of Medicine)

medimetriks pharmaceuticals, inc. - ketoconazole (unii: r9400w927i) (ketoconazole - unii:r9400w927i) - ketoconazole 20 mg in 1 g - ketodan® foam, 2% is indicated for the topical treatment of seborrheic dermatitis in immunocompetent patients 12 years of age and older. limitations of use safety and efficacy of ketodan® foam, 2% for treatment of fungal infections have not been established. none. risk summary there are no available data on ketoconazole foam, 2% use in pregnant women to identify a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. no reproductive studies in animals have been performed with ketoconazole foam, 2%. in animal reproduction studies with pregnant mice, rats and rabbits both embryotoxic and developmental effects (structural abnormalities) were observed following oral dosing of ketoconazole during organogenesis. assuming equivalent systemic absorption of topical and oral ketoconazole doses and a ketoconazole foam, 2% maximum recommended human dose (mrhd) of 8 grams (equivalent to 160 mg ketoconazole), embryotoxic effects were observed at 0.8 to 2.4 times the mrhd and deve

Yhdysvallat - englanti - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - ketoconazole (unii: r9400w927i) (ketoconazole - unii:r9400w927i) - ketoconazole 200 mg

Yhdysvallat - englanti - NLM (National Library of Medicine)

janssen pharmaceuticals, inc. - ketoconazole (unii: r9400w927i) (ketoconazole - unii:r9400w927i) - ketoconazole 20 mg in 1 ml - nizoral® (ketoconazole) 2% shampoo is indicated for the treatment of tinea (pityriasis) versicolor caused by or presumed to be caused by pityrosporum orbiculare (also known as malassezia furfur or m. orbiculare ). note: tinea (pityriasis) versicolor may give rise to hyperpigmented or hypopigmented patches on the trunk which may extend to the neck, arms and upper thighs. treatment of the infection may not immediately result in normalization of pigment to the affected sites. normalization of pigment following successful therapy is variable and may take months, depending on individual skin type and incidental sun exposure. although tinea versicolor is not contagious, it may recur because the organism that causes the disease is part of the normal skin flora. nizoral® (ketoconazole) 2% shampoo is contraindicated in persons who have known hypersensitivity to the active ingredient or excipients of this formulation.

Yhdysvallat - englanti - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - ketoconazole (unii: r9400w927i) (ketoconazole - unii:r9400w927i) - ketoconazole 20.5 mg in 1 ml